SOURCE-LINKED STUDY SUMMARY
Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point.
Abstract summarizedQuality not appraised
- What was studied
- This mechanistic trial examined how testosterone raises hemoglobin and hematocrit through erythropoietin and iron-regulatory pathways.
- Who / model studied
- Participants were older men with mobility limitations; responses were also assessed in the subgroup with anemia.
- Studied dose & schedule
- Men received testosterone gel or placebo daily for 6 months; the abstract did not report the testosterone dose.
- What the study found
- Testosterone increased hemoglobin by 7% and hematocrit by 10%, with early increases in EPO and decreases in ferritin and hepcidin. By month 6, EPO remained nonsuppressed despite higher hemoglobin, supporting a recalibrated EPO–hemoglobin set point.
- Limitations & context
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1093/gerona/glt154